Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 7/20 | 0.43 |
| ▸ | CETP | P11597 | 3/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 6/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13609025 | 1.00 | KLK7 (0.43) | KLK7CETPNR1H2NR1H3PLA2G10 | |
| SCHEMBL18711884 | 0.87 | CETP (0.42) | KLK7CETPNR1H2NR1H3KLK5 | |
| SCHEMBL759185 | 0.84 | CETP (0.52) | KLK7CETPNR1H2NR1H3PLA2G10 | |
| SCHEMBL13609033 | 0.84 | CETP (0.46) | KLK7CETPNR1H2NR1H3PLA2G10 | |
| SCHEMBL14311138 | 0.84 | CETP (0.46) | KLK7CETPNR1H2NR1H3PLA2G10 | |
| SCHEMBL9885652 | 0.84 | CETP (0.52) | KLK7CETPNR1H2NR1H3PLA2G10 | |
| SCHEMBL3950489 | 0.81 | KLK7 (0.43) | KLK7CETPNR1H2NR1H3KLK5 | |
| SCHEMBL14319901 | 0.81 | CHRM2 (0.37) | CETPNR1H2ABCB1 | |
| SCHEMBL13609043 | 0.81 | CHRM2 (0.37) | CETPNR1H2ABCB1 | |
| SCHEMBL3951314 | 0.80 | CETP (0.40) | KLK7CETPNR1H2NR1H3KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049517-B1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| US-20090286790-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| EP-2049517-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008009435-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009435-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286790-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | KLK7 2016/4885CETP 1/4885NR1H2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.